136 related articles for article (PubMed ID: 38118215)
41. EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis.
Du TQ; Liu R; Zhang Q; Luo H; Liu Z; Sun S; Wang X
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358967
[TBL] [Abstract][Full Text] [Related]
42. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
[TBL] [Abstract][Full Text] [Related]
43. Non-coding RNAs-EZH2 regulatory mechanisms in cervical cancer: The current state of knowledge.
Zheng J; Chen L
Biomed Pharmacother; 2022 Feb; 146():112123. PubMed ID: 34915417
[TBL] [Abstract][Full Text] [Related]
44. Targeting EZH2 for cancer therapy: progress and perspective.
Han Li C; Chen Y
Curr Protein Pept Sci; 2015; 16(6):559-70. PubMed ID: 25854924
[TBL] [Abstract][Full Text] [Related]
45. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.
Zhang L; Li HT; Shereda R; Lu Q; Weisenberger DJ; O'Connell C; Machida K; An W; Lenz HJ; El-Khoueiry A; Jones PA; Liu M; Liang G
Cancer Lett; 2022 Nov; 548():215899. PubMed ID: 36087682
[TBL] [Abstract][Full Text] [Related]
46. Long Non-coding RNA
Endo I; Amatya VJ; Kushitani K; Nakagiri T; Aoe K; Takeshima Y
Anticancer Res; 2023 Dec; 43(12):5367-5376. PubMed ID: 38030172
[TBL] [Abstract][Full Text] [Related]
47. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
Koumangoye RB; Andl T; Taubenslag KJ; Zilberman ST; Taylor CJ; Loomans HA; Andl CD
Mol Cancer; 2015 Feb; 14():24. PubMed ID: 25644061
[TBL] [Abstract][Full Text] [Related]
48. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
49. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
50. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
Eich ML; Athar M; Ferguson JE; Varambally S
Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
[TBL] [Abstract][Full Text] [Related]
51. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
52. circEZH2
Su Z; Zhang M; Luo H; Zhong J; Tan J; Xu Y; Pan X; Zeng H; Nie L; Xu M; Chen N; Chen X; Zhou Q
Cancer Sci; 2023 Apr; 114(4):1378-1395. PubMed ID: 36519785
[TBL] [Abstract][Full Text] [Related]
53. lncRNA HCP5 acts as a ceRNA to regulate EZH2 by sponging miR‑138‑5p in cutaneous squamous cell carcinoma.
Zou S; Gao Y; Zhang S
Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195851
[TBL] [Abstract][Full Text] [Related]
54. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
Kim J; Lee Y; Lu X; Song B; Fong KW; Cao Q; Licht JD; Zhao JC; Yu J
Cell Rep; 2018 Dec; 25(10):2808-2820.e4. PubMed ID: 30517868
[TBL] [Abstract][Full Text] [Related]
55. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
56. EZH2, an epigenetic driver of prostate cancer.
Yang YA; Yu J
Protein Cell; 2013 May; 4(5):331-41. PubMed ID: 23636686
[TBL] [Abstract][Full Text] [Related]
57. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
Chen Q; Zheng PS; Yang WT
Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
[TBL] [Abstract][Full Text] [Related]
58. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375
[TBL] [Abstract][Full Text] [Related]
59. miR‑92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2.
Liu F; Sang M; Meng L; Gu L; Liu S; Li J; Geng C
Int J Oncol; 2018 Oct; 53(4):1505-1515. PubMed ID: 30066891
[TBL] [Abstract][Full Text] [Related]
60. Review: Targeting EZH2 in neuroblastoma.
Gao J; Fosbrook C; Gibson J; Underwood TJ; Gray JC; Walters ZS
Cancer Treat Rev; 2023 Sep; 119():102600. PubMed ID: 37467626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
